Royalty Pharma Plc Cl A (RPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 929,026 | 950,052 | 1,764,644 | 843,000 | 477,010 |
| Marketable Securities | 58,200 | 48,500 | 38,500 | 29,000 | 18,300 |
| Receivables | 26,956 | 24,901 | 23,580 | 22,227 | 22,405 |
| Other current assets | 787,957 | 770,742 | 752,390 | 665,492 | 756,478 |
| TOTAL | $1,802,139 | $1,794,195 | $2,579,114 | $1,559,719 | $1,274,193 |
| Non-Current Assets | |||||
| PPE Net | 15,127,160 | 14,968,070 | 13,889,890 | 13,465,410 | 14,088,660 |
| Investments And Advances | 1,259,884 | 1,237,184 | 1,160,016 | 1,101,272 | 1,012,481 |
| Other Non-Current Assets | 33,536 | 42,796 | 27,554 | 4,488 | 6,519 |
| TOTAL | $16,420,580 | $16,248,050 | $15,077,460 | $14,571,170 | $15,107,660 |
| Total Assets | $18,222,710 | $18,042,240 | $17,656,580 | $16,130,890 | $16,381,850 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 997,773 | 996,942 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 89,181 | 101,204 | 121,956 | 102,960 | 98,320 |
| Accrued Expenses | 98,062 | 38,412 | 56,252 | 12,595 | 51,682 |
| Other current liabilities | 68,600 | 31,200 | 97,493 | 9,019 | 11,375 |
| TOTAL | $1,253,616 | $1,167,758 | $275,701 | $124,574 | $161,377 |
| Non-Current Liabilities | |||||
| Long Term Debt | 6,614,653 | 6,610,437 | 7,602,019 | 6,139,376 | 6,135,285 |
| Other Non-Current Liabilities | -114,057 | -256,791 | -65,332 | 12,271 | -222,346 |
| TOTAL | $6,626,733 | $6,616,017 | $7,629,060 | $6,142,596 | $6,136,185 |
| Total Liabilities | $7,880,349 | $7,783,775 | $7,904,761 | $6,267,170 | $6,297,562 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 576,453 | 589,183 | 593,459 | 597,437 | 597,435 |
| Common Shares | 108 | 108 | 108 | 108 | 108 |
| Retained earnings | 2,845,653 | 2,764,685 | 2,378,251 | 2,427,448 | 2,517,583 |
| Other shareholders' equity | 3,396,127 | 3,388,935 | 3,275,905 | 3,364,311 | 3,558,164 |
| TOTAL | $10,342,370 | $10,258,470 | $9,751,818 | $9,863,716 | $10,084,290 |
| Total Liabilities And Equity | $18,222,719 | $18,042,245 | $17,656,579 | $16,130,886 | $16,381,852 |